MAGE-A3161-175 contains an HLA-DRβ4 restricted natural epitope poorly formed through indirect presentation by dendritic cells

Cancer Immunology, Immunotherapy

Volumn 57, Issue 2, 2008, Pages 207-215

  Marturano, Jill ^a   Longhi, Renato ^b   Casorati, Giulia ^a   Protti, Maria Pia ^a,c  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b CNR   (Italy)

^c NONE   (Italy)

Author keywords

Antigen processing; CD4+ T cells; MAGE A3; MHC class II epitopes; Native epitopes

Indexed keywords

EPITOPE; HLA DR ANTIGEN; HLA DRBETA4 ANTIGEN; MELANOMA ANTIGEN 3; PROTEIN; PROTEINASE; UNCLASSIFIED DRUG;

ANTIGEN PRESENTATION; ARTICLE; CD4+ T LYMPHOCYTE; CELL COMPARTMENTALIZATION; CELL LYSATE; DENDRITIC CELL; ENDOSOME; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL; LYSOSOME; MELANOMA CELL; MOLECULAR RECOGNITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; FLOW CYTOMETRY; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS;

EID: 36349030248     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-007-0364-6     Document Type: Article

References (25)

1. Antoniou AN, Blackwood SL, Mazzeo D, Watts C (2000) Control of antigen presentation by a single protease cleavage site. Immunity 12:391-398
2. + T lymphocytes. J Exp Med 189:767-778
3. + T-cell epitopes on the tumor antigen MAGE-3. Blood 101(3):1038-1044
4. + T cells of lung cancer patients. J Immunol 176(8):5093-5099
5. Curnis F, Gasparri A, Sacchi A, Longhi R, Corti A (2004) Coupling tumor necrosis factor-alpha with alphaV integrin ligands improves its antineoplastic activity. Cancer Res 64:565-571
6. Fleischhauer K, Tanzarella S, Russo V, Sensi ML, van der Bruggen P, Bordignon C, Traversari C (1997) Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J Immunol 159:2513-2521
7. Gaugler B, van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930
8. Knutson KL, Disis ML (2005) Augmenting T helper cell immunity in cancer. Curr Drug Targets Immune Endocr Metabol Disord 5(4):365-371
9. Kobayashi H, Song Y, Hoon DSB, Appella E, Celis E (2001) Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Cancer Res 61:4773-4778
10. Lich JD, Elliott JF, Blum JS (2000) Cytoplasmic processing is a prerequisite for presentation of an endogenous antigen by major histocompatibility complex class II proteins. J Exp Med 191:1513-1523
11. + cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:8871-8876
12. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J (2003) Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 33:1250-1259
13. Paludan C, Schmid D, Landthaler M, Vockerodt M, Kube D, Tuschl T, Munz C (2005) Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science 307:593-596
14. + T cell responses in antitumor immunity. Curr Opin Immunol 10:588-594
15. Pluger EB, Boes M, Alfonso C, Schroter CJ, Kalbacher H, Ploegh HL, Driesses C (2002) Specific role of cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 32:467-476
16. Protti MP, Manfredi AA, Straub C, Wu XD, Howard JF Jr, Conti-Tronconi (1990) Use of synthetic peptides to establish anti-human acetylcholine receptor CD4+ cell lines from myasthenia gravis patients. J Immunol 144(5):1711-1720
17. + cytolytic T lymphocytes. Cancer Res 60:6272-6275
18. Schultz ES, Schuler-Thurner B, Stroobant V, Jenne L, Berger TG, Thielemanns K, van der Bruggen P, Schuler G (2004) Functional analysis of tumor-specific Th cell responses detected in melanoma patients after dendritic cell based immunotherapy. J Immunol 172:1304-1310
19. Sercarz EE, Maverakis E (2003) Mhc-guided processing: binding of large antigen fragments. Nat Rev Immunol 3:621-629
20. Sturniolo T, Bono E, Ding J, Raddrizzani L, Tuereci O, Sahin U, Braxenthaler M, Gallazzi F, Protti MP, Sinigaglia F, Hammer J (1999) Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 17:555-561
21. + T cells and their role in antitumor immune response. J Exp Med 189:753-756
22. Trombetta ES, Mellman I (2005) Cell biology of antigen processing in vitro and in vivo. Ann Rev Immunol 23:975-1028
23. van der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, van den Eynde BJ, Brasseur F, Boon T (2002) Tumor-specific shared antigenic peptides recognised by human T cells. Immunol Rev 188:51-64
24. Wack A, Montagna D, Dellabona P, Casorati G (1996) An improved PCR-heteroduplex method permits high sensitivity detection of clonal expansion in complex T cell population. J Immunol Meth 196:181-192
25. + T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol 171:219-225